Volume 4, Issue 2 (2024)

This study provides a 2024 update on survival outcomes and the frequency of hematologic complications, specifically lymphocytopenia, neutropenia, and thrombocytopenia, in patients treated with axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) CAR-T cell therapies. The study examined 56 patients diagnosed with diffuse large B-cell lymphoma who underwent CAR-T cell therapy from 2019 to March 2024. Among them, 34 patients received axi-cel (group A), and 22 patients were treated with

The purpose of this research is to analyze the epidemiological trends of female-specific cancers in Malaysia. The review included studies from various sources, including the Asian Pacific Journal for Cancer Prevention, as well as databases like PubMed, Medline, Wiley Online Library, and ProQuest Central. The selected studies were published in various languages and covered all types of trials on patients of any age, between 1980 and 2016. The findings highlighted that Chinese women had the highes

This study investigated the biological effects of coriander root extract on gastric cancer cells, specifically focusing on how it affected the proliferation and motility of the BGC-823 cell line. The findings showed that exposure to the extract led to a sharp drop in colony survival and significantly hindered cellular proliferation. In addition, the extract reduced the invasive behavior of the cancer cells, impaired their ability to close scratch wounds, and interfered with their ability to migr

Radiotherapy for head and neck cancer usually involves administering a total dose ranging from 6000-7000 cGy, given daily over a 6-7 week period, and is associated with a variety of oral complications. These complications include oral mucositis, oral pain, decreased saliva secretion, an increased likelihood of dental caries, limited mouth opening, and osteoradionecrosis. This cross-sectional study aimed to assess the knowledge of Saudi dental professionals through an online survey, with 463 dent

Research indicates a growing association between breast cancer and increased mortality rates across the globe. Various risk factors, such as obesity, high-fat diets, lack of physical exercise, alcohol use, oral contraceptive consumption, genetic mutations, and others, contribute to the development of breast cancer. In addition, some studies have pointed to the role of the breast cancer gene 1 (BRCA1) in breast cancer onset. The objective of this study was to investigate how thiophene (1) and its

Despite being an uncommon hematologic malignancy in adults, acute lymphoblastic leukemia (ALL) remains a highly aggressive disease, with long-term survival rates reported between 30% and 40%. A thorough understanding of the biology of the disease is essential for the effective management of ALL, enabling the application of personalized therapeutic strategies, given the heterogeneity of patient presentations. This has further facilitated the development of targeted therapies and the integration o

Next-generation sequencing (NGS) has emerged as a molecular technique capable of generating an extensive genomic characterization of non-small cell lung cancer (NSCLC). Because a wide range of biomarker-based therapeutic options now exist, molecular laboratories have become essential in guiding clinical decision-making. In this report, we present the performance of an NGS assay accredited under UNE-EN ISO 15189:2022 in a series of 350 individuals. The most common alterations involved TP53 (51.0%

Sentinel lymph node biopsy (SLNB) has largely replaced axillary lymph node dissection (ALND) for breast cancer (BC) patients receiving neo-adjuvant chemotherapy (NAC). It is routinely used in individuals who present with clinically node-negative (cN0) disease, but its value in those who begin as clinically node-positive (cN+) remains unsettled. We retrospectively reviewed BC cases treated with NAC followed by SLNB to determine the relevance of this approach. Clinical features and oncologic outco

This retrospective review from a single institution aimed to outline the clinical profile of adult individuals with solid malignancies who entered oncology trials across a decade (2010–2019) and to quantify drug cost avoidance (DCA) attributable to sponsor-funded treatments. Sponsor-supported pharmaceutical costs were estimated using the annual market price of each antineoplastic product that Vall d’Hebron University Hospital (HUVH) would otherwise have paid. Across the study window, 2930 trials

The GIM 13-AMBRA project is a longitudinal cohort investigation designed to report on treatment patterns and associated outcome metrics in 939 patients with HER2-negative metastatic breast cancer (MBC). In both Luminal (30.2%) and TNBC (33.3%) groups, first-line care most often involved taxane-based therapy, either alone or with targeted agents—most commonly Bevacizumab. The median PFS1 reached 12.5 months (95% CI 16.79-19.64), showing no subtype-related differences. In contrast, the median TTC1